Dermata Therapeutics, Inc. DRMA
1.14
(0.03)
(2.56%)
as of 25 Sep
- Market cap
- $4.7M
- P/E
- 0.0×
Follow DRMA
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
4.56 | 4.79 | 7.09 | 2.81 |
Net Debt/EBITDA |
2.65 | 3.96 | 3.61 | 1.46 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.07 | 0.71 | 1.34 | 0.82 | |
Capex/Depreciation |
— | — | — | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(1.76) | (1.44) | (0.64) | (0.63) | |
Cash per Share |
4.54 | 8.12 | 1.80 | 1.10 | |
Shareholders Equity per Share |
3.86 | 6.72 | 1.66 | 0.87 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.86 | 6.72 | 1.66 | 0.87 | |
Free Cash Flow |
(1.80) | (1.33) | (2.48) | (2.53) | |
Working Capital |
3.96 | 6.22 | 6.41 | 3.32 | |
Capital Expenditures |
— | — | — | (0.11) | |
Net Current Asset Value |
3.96 | 6.22 | 6.41 | 3.32 | |
| Other line items | |||||
Quick Ratio |
4.20 | 4.59 | 6.60 | 2.41 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.76) | (1.44) | (0.64) | (0.60) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.03) | |
Average Payables |
0.66 | 0.63 | 0.86 | 0.77 | |
Average Assets |
5.88 | 5.70 | 8.74 | 5.98 | |
Average Common Equity |
4.35 | 3.89 | 6.86 | 4.55 | |
Capex to Sales |
— | — | — | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates